Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Rapid Biopharma Response To COVID-19 Enabled By Decades Of R&D Investment, Firms Say

Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.

Coronavirus COVID-19 Innovation

Biopharma, Payers Seek National Guidelines For Prescribing Potential COVID-19 Drugs

Guidelines for US health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.

Coronavirus COVID-19 Market Access

Inside The COVID-19 Bill: Breaking Down The Pharma Policy Provisions

What's in – and what fell out of – the massive US stimulus package.

Coronavirus COVID-19 Legislation

Part D Plans Would Need To Cover COVID-19 Drugs Without Cost Sharing Under House Bill

US House leadership's COVID-19 aid package focuses on cost sharing relief for patients to ensure access to treatments and vaccines for the virus. The Senate's legislative proposal tried to provide Medicare reimbursement incentives to providers to facilitate uptake, but some of those provisions were later dropped.

Coronavirus COVID-19 Medicare

Antibiotics May Finally Get Better Medicare Payments Under US Senate COVID-19 Aid Package

Provisions adapted from DISARM Act would carve out antimicrobials from hospital bundled payments and allow reimbursement equal to 100% of a drug’s average sales price.

Reimbursement Medicare

Medicare Part B, Breakthrough Drugs Get Reimbursement Boost In Senate COVID-19 Bill

Legislation allows sponsors to request HCPCS code even before US FDA approval, but would extend the sequester until 2030 to pay for the temporary increase in payments for Part B drugs.

Medicare Coronavirus COVID-19
See All
UsernamePublicRestriction

Register